LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

Shots:

  • Ubiquigent to receive up front, option exercise fee and milestone payment. Leo Pharma to get an option to access two novel therapies
  • The partnership will strengthen Leo Pharma’s research capabilities and disease understanding and extending its expertise in medical dermatology worldwide
  • The option agreement follows 2018 agreement signed b/w Ubiquigent and LEO Pharma to evaluate a collection of Ubiquigent’s novel compounds across LEO Pharma’s in-house disease-relevant assays

Click here to­ read full press release/ article | Ref: Businesswire | Image: Julia